News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
283,113 Results
Type
Article (14729)
Company Profile (68)
Press Release (268313)
Multimedia
Podcasts (78)
Webinars (13)
Section
Business (101461)
Career Advice (468)
Deals (15516)
Drug Delivery (102)
Drug Development (36993)
Employer Resources (51)
FDA (6472)
Job Trends (6285)
News (151429)
Policy (14198)
Tag
2025 Best Places to Work (7)
2026 Best Places to Work (13)
2027 BioCapital Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
40 Under 40 (2)
Academia (469)
Accelerated approval (33)
ADA (11)
Adcomms (9)
Allergies (117)
Alliances (23382)
ALS (87)
Alzheimer's disease (588)
Antibody-drug conjugate (ADC) (240)
Approvals (6933)
Artificial intelligence (357)
ASCO (114)
Autoimmune disease (118)
Automation (26)
Bankruptcy (155)
Belgium (6)
Best Places to Work (4385)
BIO (26)
Biologics (49)
BIOSECURE Act (9)
Biosimilars (199)
BioSpace Insights (72)
Biotechnology (30)
Bispecific (14)
Bladder cancer (61)
Brain cancer (45)
Breast cancer (254)
Cancer (2099)
Cardiovascular disease (250)
Career advice (430)
Career pathing (15)
CAR-T (81)
CDC (11)
CDMO (101)
Celiac Disease (1)
Cell therapy (234)
Cervical cancer (25)
Clinical research (33353)
Collaboration (1147)
Commercialization (37)
Company closure (3)
Compensation (483)
Complete response letters (54)
COVID-19 (799)
CRISPR (68)
CRO (4)
C-suite (860)
Cystic fibrosis (68)
Data (3290)
Decentralized trials (2)
Denatured (19)
Depression (68)
Dermatology (41)
Diabetes (200)
Diagnostics (1537)
Digital health (19)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (215)
Drug pricing (126)
Drug shortages (16)
Duchenne muscular dystrophy (119)
Earnings (35059)
Editorial (25)
Employer branding (4)
Employer resources (47)
ESMO (122)
Events (40810)
Executive appointments (708)
Eye disease (4)
FDA (8246)
Fibrodysplasia Ossificans Progressiva (10)
Fragile X (4)
Friedreich's ataxia (3)
Frontotemporal dementia (6)
Funding (668)
Gene editing (104)
Generative AI (38)
Gene therapy (240)
GLP-1 (533)
Government (1457)
Grass and pollen (4)
Guidances (178)
Healthcare (3701)
Hematology (77)
HIV (23)
Huntington's disease (16)
Idiopathic pulmonary fibrosis (4)
IgA nephropathy (72)
Immunology and inflammation (103)
Immuno-oncology (47)
Indications (139)
Infectious disease (919)
Inflammatory bowel disease (98)
Inflation Reduction Act (7)
Influenza (31)
Intellectual property (169)
Interviews (59)
IPO (5958)
IRA (33)
Job creations (2063)
Job search strategy (378)
JPM (29)
Kidney cancer (19)
Kidney disease (62)
Labor market (50)
Layoffs (226)
Leadership (14)
Legal (3458)
Licensing (82)
Liver cancer (27)
Longevity (18)
Lung cancer (299)
Lung diease (5)
Lymphoma (187)
Machine learning (17)
Management (18)
Manufacturing (768)
Marketing (21)
MASH (107)
Medical affairs (3)
Medical device (1331)
Medtech (1358)
Melanoma (58)
Mergers & acquisitions (10206)
Metabolic disorders (671)
Middle East (1)
mRNA (81)
Multiple sclerosis (74)
Multispecific (1)
NASH (15)
Netherlands (7)
Neurodegenerative disease (145)
Neuropsychiatric disorders (57)
Neuroscience (1254)
Neurotech (2)
NextGen: Class of 2026 (1589)
Non-profit (615)
Now hiring (31)
Obesity (344)
Opinion (158)
Ovarian cancer (83)
Pain (169)
Pancreatic cancer (86)
Parkinson's disease (130)
Partnered (15)
Patents (348)
Patient advocacy (1)
Patient recruitment (237)
Patient selection (33)
Peanut (18)
People (30803)
Peptides (19)
Pharmaceutical (34)
Pharmacy benefit managers (20)
Phase 1 (8605)
Phase 2 (14061)
Phase 3 (12779)
Pipeline (5243)
Policy (167)
Postmarket research (1407)
Preclinical (3467)
Press Release (25)
Prostate cancer (135)
Psychedelics (32)
Radioligand (1)
Radiopharmaceuticals (193)
Rare diseases (610)
Real estate (2674)
Recruiting (19)
Regenerative medicine (7)
Regulatory (11979)
Reports (24)
Research institute (588)
Resumes & cover letters (55)
Rett syndrome (18)
RNA editing (10)
RSV (29)
Saudi Arabia (1)
Schizophrenia (105)
Series A (134)
Series B (75)
Series C (1)
Service/supplier (1)
Sickle cell disease (68)
Special edition (15)
Spinal muscular atrophy (86)
Sponsored (13)
Startups (1665)
State (2)
Stem cells (2)
Stomach cancer (8)
Substance use disorders (7)
Supply chain (78)
Switzerland (13)
Tariffs (72)
The Weekly (57)
Vaccines (317)
Venture capital (57)
Weight loss (193)
Wet AMD (4)
Women's health (69)
Worklife (5)
Date
Last 7 days (220)
Last 30 days (1162)
Last 365 days (10643)
2026 (9833)
2025 (10753)
2024 (12505)
2023 (14281)
2022 (19596)
2021 (20092)
2020 (19043)
2019 (14888)
2018 (11714)
2017 (13899)
2016 (13131)
2015 (15487)
2014 (12446)
2013 (10610)
2012 (11414)
2011 (11963)
2010 (10933)
Location
Africa (328)
Alabama (25)
Alaska (1)
Arizona (111)
Arkansas (4)
Asia (21682)
Australia (2790)
California (4736)
Canada (2141)
China (961)
Colorado (210)
Connecticut (208)
Delaware (206)
Europe (42879)
Florida (898)
Georgia (90)
Hawaii (2)
Idaho (11)
Illinois (548)
India (105)
Indiana (382)
Iowa (3)
Japan (459)
Kansas (93)
Kentucky (23)
Louisiana (8)
Maine (2)
Maryland (585)
Massachusetts (3816)
Michigan (59)
Minnesota (245)
Mississippi (2)
Missouri (41)
Montana (9)
Nebraska (8)
Nevada (26)
New Hampshire (9)
New Jersey (2132)
New Mexico (7)
New York (1359)
North Carolina (873)
North Dakota (2)
Northern California (2296)
Ohio (117)
Oklahoma (6)
Oregon (17)
Pennsylvania (1018)
Puerto Rico (23)
Rhode Island (19)
South America (510)
South Carolina (16)
Southern California (2107)
Tennessee (84)
Texas (663)
United States (18709)
Utah (78)
Vermont (1)
Virginia (252)
Washington D.C. (42)
Washington State (349)
West Virginia (1)
Wisconsin (78)
Wyoming (2)
283,113 Results for "faraday pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Faraday Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 Iocyte AMI-3 Trial of FDY-5301
Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage following acute ST-elevation myocardial infarction (STEMI) through the reduction of reperfusion injury during percutaneous coronary intervention (PCI), today announced completion of enrollment in its ongoing pivotal Phase 3 Iocyte AMI-3 trial of FDY-5301.
June 11, 2024
·
3 min read
Press Releases
Faraday Pharmaceuticals to Participate in Jefferies London Healthcare Conference
November 6, 2024
·
1 min read
Press Releases
Faraday Pharmaceuticals to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
February 5, 2025
·
1 min read
Press Releases
Faraday Pharmaceuticals to Host Satellite Symposium at SCAI 2025 on Exploring New Frontiers in Reducing Ischemia-Reperfusion Injury
April 25, 2025
·
5 min read
Drug Development
Faraday Pharmaceuticals Announces Agreement with FDA on Interim Analysis of Phase 3 IOCYTE AMI-3 Trial Data and EU Notice of Intention to Grant Patent
Faraday Pharmaceuticals, Inc. today announced its agreement with the Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) amendment, enabling the company to expedite its planned Phase 3 study interim analysis.
January 4, 2024
·
4 min read
Business
Faraday Pharmaceuticals to Host KOL Webinar on the Unmet Need in the Prevention of Ischemia-Reperfusion Injury in Acute STEMI
July 16, 2024
·
6 min read
Press Releases
Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan
November 16, 2026
·
4 min read
Press Releases
ConV2X Releases Final Agenda Focused on AI, Clinical Development, FDA Regulation and Pharmaceutical Data Integrity
ConV2X Releases Final Agenda Focused on AI, Clinical Development, FDA Regulation and Pharmaceutical Data Integrity
September 8, 2026
·
1 min read
Drug Development
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial InfarctionIocyte AMI-3 Trial
Faraday Pharmaceuticals, Inc., today announced the enrollment of the first patient in its Iocyte AMI-3 study — a Phase 3 clinical trial assessing the efficacy and safety of FDY-5301 in reducing cardiovascular (CV) death and heart failure in anterior ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous intervention (PCI).
May 10, 2022
·
4 min read
Drug Development
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study for ICU-Acquired Weakness
Faraday Pharmaceuticals, Inc., a biopharmaceutical company dedicated to improving the quality of life for patients experiencing potentially life-changing critical illness by focusing on muscle health, announced the enrollment of its first patient in a Phase 2 study of FDY-5301.
October 14, 2021
·
2 min read
1 of 28,312
Next